• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hercules Capital Inc. filed SEC Form 8-K: Regulation FD Disclosure

    3/5/25 7:53:55 AM ET
    $HTGC
    Investment Managers
    Finance
    Get the next $HTGC alert in real time by email
    8-K
    false 0001280784 0001280784 2025-03-05 2025-03-05 0001280784 htgc:CommonStockParValueZeroPointZeroZeroOnePerShareMember 2025-03-05 2025-03-05 0001280784 us-gaap:DeferrableNotesMember 2025-03-05 2025-03-05

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 5, 2025

     

     

    Hercules Capital, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Maryland   814-00702   74-3113410

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File No.)

     

    (I.R.S. Employer

    Identification No.)

     

    1 North B Street, Suite 2000  
    San Mateo, CA   94401
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (650) 289-3060

    Not Applicable

    (Former name or address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on

    which registered

    Common Stock, par value $0.001 per share   HTGC   New York Stock Exchange
    6.25% Notes due 2033   HCXY   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 7.01.

    Regulation FD Disclosure.

    On March 5, 2025, Hercules Capital, Inc. (the “Company”) announced that it plans to make an offering of $250.0 million aggregate principal amount of its Convertible Unsecured Notes due 2028 (the “Convertible Notes”). The Company plans to grant the initial purchasers an option to purchase up to an additional $37.5 million principal amount of the Convertible Notes to cover overallotments, if any. The Convertible Notes will be offered only to qualified institutional buyers (as defined in the Securities Act of 1933, as amended (the “Securities Act”)) pursuant to Rule 144A under the Securities Act and to certain non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed.

    The Convertible Notes will be unsecured, will pay interest semiannually and will be convertible under specified circumstances based on a conversion rate to be determined. Upon conversion, the Company will pay or deliver, at the Company’s election, cash, shares of the Company’s common stock or a combination of cash and shares of common stock, subject to an irrevocable settlement method election that may be made by the Company. The Company will not have the right to redeem the Convertible Notes prior to maturity. The Convertible Notes will mature on September 1, 2028, unless repurchased or converted in accordance with their terms prior to such date. The interest rate, initial conversion rate and other terms of the Convertible Notes are to be determined upon negotiations between the Company and the initial purchasers.

    The Company intends to use the net proceeds from this offering (i) to fund investments in debt and equity securities in accordance with its investment objective and (ii) for working capital and other general corporate purposes.

    Neither the Convertible Notes nor the common stock that may be issued upon conversion thereof will be registered under the Securities Act. Neither the Convertible Notes nor the common stock that may be issued upon conversion thereof may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

    In addition, on March 5, 2025, the Company issued a press release announcing that it plans to make the offering. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.

    The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The furnishing of this information pursuant to Item 7.01 shall not be deemed an admission by the Company as to the materiality of such information.

     

    Item 9.01

    Financial Statements and Exhibits

     

    (d)

    Exhibits

     

    99.1    Press Release of Hercules Capital, Inc., dated March 5, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        HERCULES CAPITAL, INC.
    March 5, 2025     By:  

    /s/ Seth H. Meyer

          Seth H. Meyer
          Chief Financial Officer
    Get the next $HTGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HTGC

    DatePrice TargetRatingAnalyst
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    11/21/2023$17.00Neutral
    UBS
    8/30/2023$17.50Neutral → Buy
    Compass Point
    8/4/2023$13.50 → $17.00Underperform → Mkt Perform
    Keefe Bruyette
    4/6/2023$16.00Neutral → Overweight
    Piper Sandler
    3/13/2023$14.50 → $10.50Mkt Perform → Underperform
    Keefe Bruyette
    7/29/2022Outperform → Perform
    Oppenheimer
    More analyst ratings

    $HTGC
    SEC Filings

    See more
    • Hercules Capital Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Hercules Capital, Inc. (0001280784) (Filer)

      5/1/25 4:30:18 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form 10-Q filed by Hercules Capital Inc.

      10-Q - Hercules Capital, Inc. (0001280784) (Filer)

      5/1/25 4:16:15 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form DEFA14A filed by Hercules Capital Inc.

      DEFA14A - Hercules Capital, Inc. (0001280784) (Filer)

      4/24/25 5:04:38 PM ET
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Crowell Gayle A bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 9% to 69,344 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:21:45 PM ET
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Financials

    Live finance-specific insights

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Reports First Quarter 2025 Financial Results

      Q1 2025 Total Gross Debt and Equity Commitments of $1.02 Billion Q1 2025 Total Gross Fundings of $539.1 Million Q1 2025 Total Investment Income of $119.5 Million Q1 2025 Net Investment Income "NII" of $77.5 Million, or $0.45 per Share Q1 2025 NII of $0.45 per Share, provides 113% Coverage of the Base Cash Distribution Received an Investment Grade Rating Upgrade to BBB (high) from Morningstar DBRS Closed Offering of $287.5 Million of 4.750% Convertible Unsecured Notes due 2028 Conservative Balance Sheet Management with Net GAAP Leverage of 97.4% and Net Regulatory Leverage of 82.7%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercule

      5/1/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

      5/8/23 5:06:26 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G/A filed by Hercules Capital Inc. (Amendment)

      SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)

      10/12/22 9:11:00 AM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)

      4/27/22 4:31:08 PM ET
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

      GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company's pemvidutide development plans and financing needs. Access to this additional capital strengthens Altimmune's ba

      5/13/25 7:00:00 AM ET
      $ALT
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hercules Capital upgraded by Keefe Bruyette with a new price target

      Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

      12/12/24 8:09:58 AM ET
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital downgraded by Compass Point with a new price target

      Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously

      1/16/24 8:29:29 AM ET
      $HTGC
      Investment Managers
      Finance
    • UBS initiated coverage on Hercules Capital with a new price target

      UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00

      11/21/23 7:31:43 AM ET
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

      SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

      11/29/23 1:01:00 PM ET
      $HTGC
      $TPVG
      Investment Managers
      Finance
      Other Consumer Services
      Consumer Discretionary
    • Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

      9/25/23 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Announces the Appointment of Ms. DeAnne Aguirre to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o

      6/24/22 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HTGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Crowell Gayle A bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 9% to 69,344 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:21:45 PM ET
      $HTGC
      Investment Managers
      Finance